Peripheral T-Cell Non-Hodgkin's Lymphoma Clinical Trial
Official title:
Phase I/II Trial of Lenalidomide in Combination With Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
A standard therapy is neither established in first-line patients nor in relapsed patients
with PTCL, and there is still an unmet medical need to identify novel efficacious and safe
therapy regimens.
The aim of this study is to evaluate the potential of a Lenalidomide plus Vorinostat and
Dexamethasone combination therapy as an effective and safe therapeutic regimen, in the
treatment of relapsed PTCL following failure of prior regimens.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment